Retraction Watch

Tracking retractions as a window into the scientific process

Archive for the ‘j materials chemistry’ Category

First author objects to retraction (his fourth) in chemistry journal

without comments

The first author of a 2013 chemistry paper is objecting to his co-authors’ decision to retract the paper, which contains duplicated figures.

We recently encountered a similar scenario with papers by first author Khalid Mahmood. In late 2015, Mahmood lost three papers in the journal ACS Applied Materials & Interfaces over duplicated images. One of the notices also indicated that the figures had “been published elsewhere and identified with different samples” — the same language used in the notice of the most recent retraction, in Journal of Materials Chemistry C.

Mahmood performed the work on the papers at Korea Advanced Institute of Science and Technology (KAIST), along with his two co-authors, Seung Bin Park and Hyung Jin Sung (also co-authors on two of the retracted papers in ACS Applied Materials & Interfaces).

Seung Bin Park, who is dean of the College of Engineering at KAIST, told us: Read the rest of this entry »

Drug paper gets a fix, notching several corrections

without comments

rsc_tb_1_3_COVER.inddThe Journal of Materials Chemistry B has issued a laundry list of corrections for a 2014 chemotherapy paper, which address re-use of “some text”, incorrectly stated doses, and miscalculations of the drug concentration, among other issues.

The paper described a new way to deliver gemcitabine via nanoparticles, focusing the drug on the tumors.

It turns out the authors’ focus wasn’t so clear when writing the paper. The researchers, at the Chinese Academy of Medical Science, Peking Union Medical College, and Tianjin University in China, said they used “some text” from two 2013 papers by a team of French oncologists “without appropriate attribution,” as well as repeatedly getting the in vivo dose wrong. The manuscript also contained several incorrect calculations of the “drug loading,” or the proportion of active drug.

Here’s the correction for “Tailor-made gemcitabine prodrug nanoparticles from well-defined drug–polymer amphiphiles prepared by controlled living radical polymerization for cancer chemotherapy” (free, but requires sign-in): Read the rest of this entry »

Chemists Bielawski and Wiggins up to eight expressions of concern, one retraction

with 7 comments


Christopher Bielawski

Two researchers who already had three expressions of concern under their belts have five more, plus a retraction.

Kelly Wiggins and Christopher Bielawski share authorship on all the papers in question. After the first set of EoCs, Bielawski, at the time a PI at UT Austin, told Chemistry and Engineering News that a “former lab member” had admitted to faking the data. The recent retraction indicates that University of Texas at Austin’s Office of Research Integrity formally investigated the lab, and determined that Bielawski was telling the truth about a former lab member being to blame.

Bielawski has since taken a post at Ulsan National Institute of Science and Technology in South Korea. He told us that move was unrelated to anything that happened at UT Austin, but declined to answer other questions. Wiggins got a postdoc at the University of Illinois, which an Illinois spokesperson confirmed lasted from July 1 2013 to January 22 2014; we’re waiting to hear back on our question about whether her departure had anything to do with misconduct.

Here’s the retraction notice for “A Mechanochemical Approach to Deracemization,” in Wiley journal Angewandte Chemie: Read the rest of this entry »